stock listing

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Rosetta Genomics disclosed it has been warned by the Nasdaq that it is not in compliance with a listing requirement.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – A Nasdaq panel has granted Pressure BioSciences' request for continued listing on the exchange, the company said today.

Separately, Nasdaq said that Rosetta must regain compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq by Aug. 8, 2011, for a minimum of 10 consecutive business days.

CombiMatrix had voluntarily applied for the transfer rather than submit a plan to the exchange to regain compliance with Nasdaq Global Market listing requirements.

The firm also reported total shareholders' equity of approximately $4.9 million, which satisfies Amex's listing requirement of $4 million.

The company's stock began trading on the Nasdaq this morning. It had traded on the Pink Sheets since being delisted in 2008.